New

Trackinsight is part of ETF One, the fully integrated ETF platform of Kepler Cheuvreux. Learn more →

Help us improve your experience. Please confirm your investor type:

Compare ETFs Easily

The Ultimate ETF Comparison Tool - Try Now!

Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.

›ETF Providers›Fidelity›FMED
ETF screener

FMED ETF · Fidelity Disruptive Medicine ETF

The FMED Exchange Traded Fund (ETF) is provided by Fidelity. This fund is actively managed; it does not track an index. This share class generates a stream of income by distributing dividends.
Last update Yesterday at 1:30 PM UTC
LIVE
CLOSED
This fund is part ofMultiple Trends1M perf.+16.51%
Last price
$25.15
1M perf.
+4.38%
1M flows
N/A
AuM
€50M
E/R
0.5%
Rating
Not rated
ESG Consensus®
esg grade icon
FMED
$25.15

Performance & flows

January 23, 2026 → April 23, 2026
0-16-14-12-10-8-6-4-202%FEBMARAPRFEBMARAPR
Create a free account to view the flows graph
FMED
$25.23
-9.11%

Historic performance and flows

1M3M1Y3Y5YMTDQTDYTD
Perf.
+4.38%
-9.12%
+9.50%
N/AN/A
+2.68%
+2.68%
-6.87%
Flows

Key fund info

This ETF's jurisdiction country is not in your region (Europe and Middle East) Â· 
Main characteristics
Issuer
CUSIP
316092147
ISIN
US3160921470
AuM
€50M
E/R
0.5%
ESG Consensus®
esg grade icon
More details
NAV
4/23/2026
$25.23
1D NAV change
-2.53%
Dividend policy
No. of holdings
66
Inception date
6/12/2023
Jurisdiction
United States
Distribution
United States
Legal structure
Open-end Investment Company
Base currency
USD
Dividend distribution
Trailing 12-month distr. yield
Distribution frequency
Last distribution
Create a free account to view dividend distribution
Classification
Product type
Asset class
Factors
N/A
Investment strategy
The fund seeks long-term growth of capital. Normally investing at least 80% of assets in securities of disruptive medicine companies.
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
half moonhalf moon double
New to Trackinsight?
For individual investors

Trackinsight
Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.
More fund data
Compare up to 3 funds
More screener filters
Choose your own screener columns from 100+ metrics
Lists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring
For professional investors

Trackinsight
Enterprise

Trackinsight Enterprise addresses the everyday operational, regulatory, and analytical pain points faced by professional and institutional ETF investors, from selection to execution.
Request a free trial
More professional services:ETF Data ServicesDue Diligence Services

Similar ETFs in your region

HELX
1M perf.
+4.86%
E/R
0.5%
GNOG
1M perf.
+7.91%
E/R
0.5%
GNOM
1M perf.
+7.91%
E/R
0.5%
CIB0
1M perf.
-0.35%
E/R
0.55%

Advertisement

Risk profile

Historical risk/return profile

3M1Y3Y5Y
Returns
-9.12%
+9.50%
N/A
N/A
Volatility
Perf./Volatility
Max drawdown
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
N/A
PRIIPS
N/A
More exposure metrics are available, exclusively in Trackinsight Enterprise

Exposure

Countries
USA
87.06%
Belgium
4.43%
France
1.93%
Canada
1.57%
Bermuda
1.54%
Switzerland
1.40%
United Kingdom
1.01%
Other
1.06%
Sectors
Health Care
81.28%
Unavailable
18.72%
Diversification
Total weight of top 15 holdings out of 66
Top 15 holdings
Data as of March 31, 2026
UCB
DANAHER
BOSTON SCIENTIFIC
COGENT BIOSCIENCES
US04016X1019
ALNYLAM PHARMACEUTICALS
INTUITIVE SURGICAL
VEEVA SYSTEMS IN
Create a free account to view top holdings
MODERNA INC
LIFESTANCE HEALTH GROUP
US9467841055
EDWARDS LIFESCIENCES
INSULET
VAXCYTE
INSMED
Create a free account to view top holdings
More risk metrics are available, exclusively in Trackinsight Enterprise

Sustainability

Integrates ESG criteria
No
SDG
More sustainability metrics are available, exclusively in Trackinsight Enterprise

Issuer

Fidelity
Fidelity ID Card
Number of funds
199
Total AuM
€186.52B
Expense ratio range
0.05% - 1.5%
Average expense ratio
0.4301%

Frequently asked questions about FMED

What does Fidelity Disruptive Medicine ETF, FMED, invest in?

FMED is a Active ETF. This ETF provides exposure to Other Equities.

What is the Total Expense ratio (TER) of FMED?

FMED carries a total expense ratio (TER) of 0.5%, indicating the annual cost for holding the fund.

When was FMED launched?

FMED was introduced to the market on June 12, 2023. It trades on United States

Who is the ETF issuer of FMED?

Fidelity Disruptive Medicine ETF, FMED, is provided by Fidelity. Learn more about Fidelity here.

What is the current assets under management (AUM) of FMED?

FMED oversees €50M in assets as of April 23, 2026.

How has FMED performed lately?

Based on data from April 23, 2026, FMED returned 4.38% over the past month, -9.12% over the last three months and -6.87% year-to-date.

Does FMED distribute dividends?

FMED follows a distributing dividend policy, meaning it pays out income to investors.

What are the main country or region exposures of FMED?

As of March 31, 2026, FMED has significant geographic allocations in USA, Belgium and France.

In which sector or theme does FMED invest in?

As of March 31, 2026, FMED focuses largely on Health Care.

How many securities does FMED hold and how diversified is it?

As of March 31, 2026, FMED holds 66 positions in its portfolio, with 47.75% of assets concentrated in its top 15 holdings.

What are the main positions in FMED?

As of March 31, 2026, FMED top three holdings include UCB, DANAHER and BOSTON SCIENTIFIC.

What is the base currency of FMED?

The base currency of FMED is USD.

Advertisement

Trackinsight

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy  |  Cookie policy  |    |  Terms of use  |  Imprint
Trackinsight